Avalanche Biotechnologies Obtains $55,000,000 Series B Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=a5901484-1358-45b6-90dc-fe4bfdc5d050
Date
4/23/2014
Company Name
Avalanche Biotechnologies
Mailing Address
1555 Adams Drive Menlo Park, CA 94025 USA
Company Description
Founded in 2006, Avalanche is a biotechnology company that develops technologies and products for sustained delivery of therapeutic proteins to the eye to treat wet age-related macular degeneration (AMD), as well as other ophthalmologic disorders, such as diabetic retinopathy, retinal degeneration, and glaucoma.
Website
http://www.avalanchebiotech.com
Transaction Type
Venture Equity
Transaction Amount
$55,000,000
Transaction Round
Series B
Proceeds Purposes
Proceeds from the Series B financing round will be used to advance the company’s clinical programs in retinal disorders, including Avalanche’s lead product, AVA-101, for wet AMD.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor